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Abstract
Purpose Effective treatment of neuropathic pain without un-
acceptable side effects is challenging. Cancer sufferers in-
creasingly live with long-term treatment-related neuropathic
pain, resulting from chemotherapy-induced peripheral neu-
ropathy (CIPN) or surgical scars. This proof-of-concept study
aimed to determine whether preclinical evidence for TRPM8
ion channels in sensory neurons as a novel analgesic target
could be translated to clinical benefit in patients with neuro-
pathic pain, using the TRPM8 activator menthol.
Patients and methods Patients with problematic treatment-
related neuropathic pain underwent a baseline assessment
using validated questionnaires, psychophysical testing, and
objective functional measures. The painful area was treated
with topical 1 % menthol cream twice daily. Assessments
were repeated at 4–6 weeks. The primary outcome was the
change in Brief Pain Inventory total scores at 4–6 weeks. Sec-
ondary outcomes included changes in function, mood and
skin sensation.
Results Fifty-one patients (female/male, 32/19) were recruited
with a median age of 61 (ranging from 20 to 89). The
commonest aetiology was CIPN (35/51), followed by scar
pain (10/51). Thirty-eight were evaluable on the primary out-
come. Eighty-two per cent (31/38) had an improvement in
total Brief Pain Inventory scores (median, 47 (interquartile
range, 30 to 64) to 34 (6 to 59), P<0.001). Improvements in
mood (P=0.0004), catastrophising (P=0.001), walking ability
(P=0.008) and sensation (P<0.01) were also observed.
Conclusion This proof-of-concept study indicates that topical
menthol has potential as a novel analgesic therapy for cancer
treatment-related neuropathic pain. Improvements in patient-
rated measures are supported by changes in objective mea-
sures of physical function and sensation. Further systematic
evaluation of efficacy is required.
Keywords Menthol . TRPM8 . Neuropathic . Pain .
Cancer . Chemotherapy
Introduction
Chronic neuropathic pain, resulting from nerve injury, is a
challenging clinical problem which is difficult to treat with
current analgesics without unacceptable side effects. It greatly
reduces quality of life, even more so than other chronic pain
states with a negative impact on mobility, function, mood and
general wellbeing [1]. The prevalence of neuropathic pain is
likely to be underestimated, but studies from North America
and Europe have found between 8 and 17 % of the population
may suffer from pain of predominantly neuropathic origin
[2–4]. Neuropathic pain associated with cancer treatment is
an increasing challenge. As the incidence of cancer increases
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and survival improves with better oncological management,
there is an increasing number of patients living with the long-
term effects of treatment such as chemotherapy-induced pe-
ripheral neuropathy (CIPN) or surgical scar pain [5, 6].
CIPN affects up to 96% of patients who receive potentially
neurotoxic chemotherapy (e.g. platinums, taxanes, vinca-
alkaloids and bortezomib), resulting in dose reduction or early
cessation of treatment for up to 50 % [7–10]. Symptoms are
commonly in a glove and stocking distribution and include
spontaneous pain, paraesthesia, allodynia (nonpainful stimuli
causing pain), hyperalgesia (increased sensitivity to painful
stimuli), hypoaesthesia (numbness) and impaired propriocep-
tion, causing difficulty with day-to-day functioning such as
fastening buttons, handling coins, walking and driving. In
our centre, 50 % of colorectal cancer patients still had symp-
toms of neuropathy 12 months after completing treatment
with curative intent [5].
Estimates for persistent neuropathic pain after cancer sur-
gery vary, with post-mastectomy and post-thoracotomy pain
occurring in 30–60 % of patients [11]. One large study after
breast cancer surgery found almost half of patients had persis-
tent pain 2 to 3 years later, with this being moderate to severe
in nearly a quarter of patients [12]. In our own centre, approx-
imately 30 % of patients had persistent post-mastectomy pain,
with a threefold increase in risk conferred by adjuvant chemo-
therapy [13]. Recent guidelines suggest the use of objective
quantifiable tests such as Quantitative Sensory Testing as clin-
ical biomarkers to strengthen the diagnosis of neuropathic
pain, which is made on history and examination [14, 15].
Treatment of neuropathic pain relies on early identification,
understanding of the initiating and sustaining pathophysiolog-
ical mechanisms and use of a range of therapeutic approaches
[16]. Evidence is accumulating which suggests that the neu-
rosensory characteristics of the pain may be the most impor-
tant factor in predicting a treatment response, rather than the
underlying aetiology [17, 18]. Current systemic therapy is
mainly oral antidepressants or anticonvulsants; however, treat-
ment often requires titration over months and is limited by
variable efficacy and unacceptable side effects [19]. Nontoxic
therapies, which reduce pain with minimal side effects, are
needed.
A new potential novel therapeutic approach has arisen as a
result of basic science findings from our translational research
group which demonstrated that endogenous neural circuitry
underlying cooling-induced analgesia may represent a novel
target for intervention. Molecular receptors for cooling have
been identified in sensory nerves with evidence for their up-
regulation in neuropathic pain models [20, 21]. Our group
identified how activation of one of these, the transient receptor
potential melastatin (TRPM)8 ion channel, by topical agents,
produced significant analgesia [22]. As a result of this work,
we successfully used topical menthol, a TRPM8 agonist, in
two cases of treatment-resistant chemotherapy-induced
peripheral neuropathy, allowing continuation of life-
prolonging treatment [23, 24]. If topical TRPM8 agonists pro-
duced profound, mechanistically novel analgesia in chronic
neuropathic pain, this would be a significant advance.
Aims
The primary aim of this study is to determine whether 4–
6 weeks of topical 1 % menthol in aqueous cream provided
effective analgesia for neuropathic pain in a proof-of-concept
study (assessed using the Brief Pain Inventory).
The secondary aims of this study is to determine whether
mood and surrogate clinical measures (biomarkers) of neuro-
pathic pain (physical function and quantitative sensory test-
ing) improved after 4–6 weeks of topical 1 % menthol in
aqueous cream.
Methods
This was an open-label proof-of-concept study. After
obtaining research ethics committee approval and written in-
formed consent, suitable patients were recruited from the Ed-
inburgh Regional Cancer Centre. For inclusion, patients had
to meet the following criteria: chronic neuropathic pain (diag-
nosed by a palliative medicine or pain medicine specialist);
stable pain, not expected to change within the following
6 weeks; an average pain severity of ≥/4 on a 0 to 10 scale;
aged 18 years or over; and either had tried conventional anti-
neuropathic agents or these were contraindicated/declined. Pa-
tients were excluded if they had any medical or psychiatric
condition that would confound the study objectives. Patients
underwent a comprehensive assessment of pain and its impact
on function immediately prior to treatment and after 2 and 4–
6 weeks of treatment, as recommended by the Initiative on
Methods, Measurement and Pain Assessment in Clinical Tri-
als (IMMPACT) [25]. Standard demographic data were col-
lected. The 1 % (−) menthol (levomenthol) in aqueous cream
was used topically. Each patient was instructed on how to
apply the cream to the affected area and corresponding der-
matomal region of spine, twice daily on a regular basis.
Each assessment comprised:
1. Validated self-report questionnaires to assess the sensory,
cognitive and affective components of pain, with higher
scores representing more severe symptoms:
a. The short-form Brief Pain Inventory (BPI): an 11-
item assessment using a 0 (no pain/interference) to
10 (worst pain/interference) rating scale of pain inten-
sity and its impact (interference with general activity,
mood, walking ability, normal work, relations with
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others, sleep and enjoyment of life over the last week).
The total BPI is the sum of all 11 items (ranging from
0 to 110), the interference subscale is the total of the
seven interference items (ranging from 0 to 70) [26].
b. Hospital Anxiety and Depression scale (HADS): with
a range of 0–21 for both anxiety and depression [27].
c. Pain Catastrophising scale: This measures rumina-
tion, magnification and helplessness. Range of 0–65,
with values of >30 thought to be of clinical signifi-
cance [28].
d. Leeds Assessment of Neuropathic Symptoms and
Signs (LANSS): is a validated screening tool for neu-
ropathic pain (range 0-24, score ≥12 is indicative of
neuropathic pain) [29].
2. Surrogate clinical biomarker measures of neuropathic
pain:
a. Objective measures of functional performance:
i. Walking ability was assessed using a GAITRite®
walking mat to measure gait velocity (cm/s) and
cadence (steps/min) [30].
ii. Hand dexterity. Patients were instructed to fill a five-
by-five slotted boardwith grooved pegs in an ordered
fashion. The time taken (s) to do this with the dom-
inant and nondominant hands was recorded [31, 32].
b. Quantitative Sensory Testing (QST) was conducted
using our well-established protocol that has been used
successfully in frail patients [33]. Skin overlying the
affected area and an unaffected control area were
assessed (either the equivalent contralateral dermato-
mal region, or for patients with bilateral peripheral
neuropathy, a more proximal unaffected area). Testing
was carried out in a quiet environment with the pa-
tient relaxed and took 20–40 min. All researchers
underwent standardised QST training to use the fol-
lowing protocol:
i. The affected area was mapped using a calibrated
brush (Senselab 0.5 mN Somedic, Sweden) moving
from normal to affected areas. Areas of abnormal
sensation were marked out on the skin. The patient
was asked to describe how this sensation compared
with the control area (hyperaesthesia, hypoaesthesia
or unchanged) and, if painful, it was rated on a 0 to
10 numerical rating scale (NRS). The area of abnor-
mal sensation was measured using tracing paper (re-
corded in cm2 for patients with scar pain) or distance
(cm) measured from the middle finger tip or great
toe for peripheral neuropathies. For the latter, the
percentage of the limb affected was calculated as a
proportion of the distance from the finger tip/great
toe to the olecranon/inferior patella border.
ii. Thermal sensory mapping was conducted in a sim-
ilar way using warm (40 °C) and cool (25 °C) rol-
lers (Rolltemp, Somedic, Sweden).
iii. Mechanical Detection Threshold (MDT) and Me-
chanical Pain Threshold (MPT) were assessed with
17 von Frey monofilaments of varying thickness,
calibrated according to the force required to make
them bend (0.026 to 110 g, Somedic, Sweden).
Using the Method of Levels the monofilaments
were applied to the skin in ascending order and
the MDT noted when felt consistently (detecting
three out of five applications). MPT was the force
when the stimulus became unpleasant and rated
using a NRS from 0 to 10.
iv. Mechanical pain sensitivity (hyperalgesia) was
tested using noxious pin prick stimulus
(NeurotipsTM Owen Mumford) and rated using an
NRS from 0 to 10.
v. Temporal summation was assessed using five rap-
idly repeated pin prick stimuli and a NRS rating.
The wind up ratio was calculated as the NRS score
(repeated stimuli)/NRS score (single stimulus) [34].
Table 1 Patients’ characteristics at baseline
Neuropathic pain aetiology Total n=51 (n (%))
CIPN 31 (61)
Chemotherapy
Oxaliplatin 21 (41)
Paclitaxel 2 (4)
Taxotere 1(2)
Bortezomib 2 (4)
Cisplatin 4(8)
Carboplatin 1(2)
Median months since last dose (IQ range) 11 (8 to 24)
Neuropathic scar pain 10 (20)
Neuropathic pain due to other causes 10 (20)
Median months of pain: all causes (IQ range) 19 (9 to 34)
Previous/current cancer diagnosis 41 (80)
Type of cancer
Colorectal 22 (43)
Multiple myeloma 2 (4)
Lung 3 (6)
Ovary 2 (4)
Breast 12 (23)
Cancer status
No recurrence 33 (65)
Local disease 6 (12)
Metastatic disease 2 (4)
IQ interquartile, CIPN chemotherapy-induced peripheral neuropathy
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Statistical analysis
Data were displayed as mean (standard deviation (SD)), me-
dian (interquartile range) or proportions as appropriate. Con-
tinuous variables at baseline and 4–6 weeks were compared
using the Wilcoxon signed rank test or paired t test as appro-
priate. The primary variable of interest was the change in pain
as assessed by the total BPI. Responders were defined as a
≥30 % reduction in total BPI, which is considered to be a
clinically meaningful improvement [35]. Responders and
nonresponders were compared, to define any patient charac-
teristics associated with a treatment response, using the
Mann–Whitney U test or two-sample t test as appropriate.
This was an exploratory analysis and a P value of <0.05 was
considered statistically significant with no correction for mul-
tiple testing.
Results
Fifty-one patients entered the study. The median age was 61
(ranging from 20 to 89), and the majority were female (32/51,
63 %). Most had been treated for cancer (41/51, 80 %) and the
majority of these were recurrence free (33/41, 80 %). The
commonest neuropathic pain aetiology was CIPN (31/51,
61 %), followed by scar pain (10/51, 20 %, most frequently
post-mastectomy) and miscellaneous reasons (10/51, 20 %)
(Table 1). Thirty (59 %) patients had tried a range of standard
analgesics and anti-neuropathic agents. During the study pe-
riod 7 (14 %), patients were on a variety of standard analge-
sics, with no relevant medication change during the study
period. Forty-four (86 %) patients were on no analgesics dur-
ing the study period.
Forty of fifty-one patients completed 4–6 weeks of treat-
ment. Ten patients discontinued the topical menthol treatment
early for the following reasons: disliked the cream (n=2),
found cream application difficult (n=2), developed brain me-
tastases (n=1), felt no benefit (n=1), pain worsened (n=2),
(resolved to baseline levels within 2 weeks of stopping men-
thol) or withdrew from the trial without giving a reason (n=2).
One patient only attended at 10 weeks after baseline, so did
not complete the 4–6-week assessment. Thirty-eight patients
had complete evaluable outcome data. All completing patients
used very similar quantities of menthol cream over the study
period (1000×g, i.e. 10 g menthol).
Change in pain scores and other patient-rated outcomes
Eighty-two per cent (31/38) of evaluable patients had an im-
provement in their pain scores. The median total BPI im-
proved from 47 (interquartile range, 30 to 64) to 34 (6 to
Table 2 Comparison of measures at baseline and after 4–6 weeks of menthol
Measure
(possible score)
Number Baseline median
(IQ range)
4–6 weeks median
(IQ range)
Mean/median of individual
changesb (95 % CI)
P value
Brief Pain Inventorya
Total BPI (0 to 110) 38 47 (30 to 64) 34 (6 to 59) −11 (−16.1 to −5.5) <0.001
Worst pain item (0 to 10) 39 6 (4 to 7) 3 (1 to 7) −1.3 (−2.1 to −0.6) 0.001
Total interference (0 to 70) 38 32 (17 to 43) 24 (3 to 37) −6.3 (−10.2 to −2.5) 0.002
HADSa
Depression (0 to 21) 38 4 (2 to 7) 4 (1 to 6) 0b (−1.6 to 0.1) 0.168c
Anxiety (0 to 21) 38 7.5 (4 to 9) 5 (2 to 8) −1.7 (−2.6 to −0.8) 0.001
Total (0 to 42) 38 12 (6 to 16) 9 (5 to 13) −2.5 (−4.1 to −0.8) 0.004
PCSa (0 to 65) 37 13 (9 to 19) 10 (2 to 17) −4.5 (−7.0 to 2.0) 0.001
LANSSa (0 to 24) 40 14 (11 to 19) 13 (8 to 19) −1.1 (−2.6 to 0.4) 0.160
Peg boarda
Dominant hand (s) 15 98 (79 to 147) 85 (77 to 103) −10.8 (−34 to 12.5) 0.337
Nondominant hand (s) 15 95 (92 to 147) 92 (76 to 102) −13.5 (−34.7 to 7.7) 0.195
GAITRite
Velocity (metres/s) 21 79 (68 to 106) 93 (79 to 113) 12.1 (3.6 to 20.6) 0.008
Cadence (steps/min) 21 100 (89 to 110) 105 (96 to 113) 6.0 (0.8 to 11.2) 0.027
BPI Brief Pain Inventory, HADS Hospital Anxiety and Depression scale, LANSS Leeds Assessment of Neuropathic Symptoms and Signs, PCS Pain
Catastrophising scale 95 % CI 95 % confidence interval, IQ range interquartile range
a Higher scores indicate more severe symptoms
bMedian change (when distribution of variables relating to the change between baseline and 4–6 weeks was not normally distributed)
c Exception—compared using paired t test when Wilcoxon signed rank test used
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59), P<0.001. There were also significant improvements in
‘worst pain’ and the pain interference subscales (Table 2). The
mean total BPI decrease was 11 (SD 16). Fifty per cent (19/38)
were responders, with 11 % (4/38) having complete pain re-
lief. All the statistically significant improvements in pain were
also clinically significant [21]. Along with the improvement in
pain scores, there were also statistically significant improve-
ments in HADS total score, HADS anxiety score and
catastrophising (Table 2). The LANSS scores, as expected,
did not demonstrate any significant treatment effect. Patients
who were taking other regular pain medication remained on
the same dose throughout the 6 weeks.
Change in quantitative sensory testing (QST), objectively
measured walking ability and hand dexterity
As well as an improvement in subjectively rated pain, there
was also an improvement in objectively measured physical
function and some QST parameters. Both walking velocity
and cadence improved over the treatment period, although
there was no significant improvement in hand dexterity
(Table 2). QSTshowed a decrease in the mechanical detection
threshold (became less numb), and for the CIPN patients, the
percentage of the distal limb skin which had abnormal
sensation in response to brush, cool and warm stimuli de-
creased and moved distally (Table 3; Fig. 1).
Comparison of responders and non responders at 4–6 weeks
Responders had a significantly greater degree of improvement
than nonresponders in catastrophising and dominant hand
dexterity but not on other variables (Table 4).
Discussion
Main finding
This is, to our knowledge, the first clinical study to report an
analgesic benefit from the application of topical menthol to
treat CIPN and Post-mastectomy Pain Syndrome (PMPS).
Eighty-two per cent of evaluable patients had an improvement
in their total pain scores after 4–6 weeks of treatment. Fifty per
cent had a clinically relevant reduction in pain scores of at
least 30 %.
Importantly, there were also improvements in objectively
measured physical function. The significant increase in walk-
ing velocity and cadence are important read-outs of increased
Table 3 Quantitative sensory testing (QST) and proportion of distal limbs with abnormal sensation to brush, cool and warm stimuli at baseline and 4–
6 weeks
Measure
(possible score)
Number Baseline median
(IQ range)
4–6 weeks median
(IQ range)
Median of individual
changesa (95 % CI)
P value
QST
Mechanical detection threshold forcec (0.026 to 110 g) 40 1.1 (0.3 to 2.9) 0.3 (0.1 to 1.1) −0.2a (−7.9 to 1.7) 0.016b
Mechanical detection threshold NRS (0 to 10) 40 0 (0.0 to 0.0) 0 (0.0 to 0.0) 0.0a (−0.3 to 0.0) 0.131b
Mechanical pain threshold forced (0.026 to 110 g) 40 34 (11 to 110) 110 (17 to 110) 0.0a (−7.4 to 31.9) 0.198b
Mechanical pain threshold NRS (0 to 10) 39 2 (0 to 4) 1 (0 to 3) −0.4 (−1.3 to 0.6) 0.445
Windup ratio 40 1 (0.0 to 2.0) 1 (0.0 to1.3) 0.0a (−2.0 to 0.2) 0.098b
Extent of abnormal receptive field
Brush stimulus
% of forearm below elbow 20 55 (2 to 73) 24 (0 to 57) −16 (−32 to 1) 0.062
% of lower leg below knee 19 65 (16 to 82) 39 (16 to 64) −13 (−26 to 0) 0.056
Cool (25 °C) stimulus
% of forearm below elbow 19 70 (34 to 88) 37 (9 to 79) −19 (−37 to −2) 0.036
% of lower leg below knee 19 67 (48 to 97) 43 (21 to 79) −24 (−36 to 12) 0.001
Warm (40 °C) stimulus
% of forearm below elbow 18 72 (50 to 88) 24 (8 to 79) −28a (−39 to −11) 0.004b
% of lower leg below knee 19 89 (78 to 93) 56 (20 to 77) −25 (−41 to −10) 0.003
NRS Numerical Rating Scale (higher scores indicate worse pain), 95 % CI 95 % confidence interval, IQ range interquartile range
aMedian change (when distribution of variables relating to the change between baseline and 4–6 weeks was not normally distributed)
b Exception—compared using paired t test when Wilcoxon signed rank test used
c Higher values indicate the skin is more numb
d Lower values indicate increased sensitivity to painful stimuli
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function. Such objective improvements in function increase
the likelihood that we are seeing a genuine response to treat-
ment. In addition, QST showed a shrinkage of the skin area
with abnormal sensation to several different stimuli (warm,
cool and mechanical). The associated changes in mechanical
detection threshold and response to warm and cold between
baseline and study endpoint again reinforce the evidence for
an objective improvement in pain as the key outcome of this
study.
Comparison with other studies
Cooling of injured areas by for example, cold compresses/
icepacks or application of menthol for pain relief has a
long history in medicine. The analgesic effect of menthol
was reported in 1870 by Wright et al. [36], and its bene-
ficial properties were known to the Ancient Greeks. More
recent case reports demonstrated potential increased effi-
cacy for neuropathic pain. While the mechanism of these
traditional treatments has long been obscure, our recent
demonstration that TRPM8 activation acts through central
inhibition of nociceptive input provides a scientific ratio-
nale for a new generation of analgesics targeting TRPM8
[22]. In fact, several members of the TRP super family
have emerged as important targets for new drugs,
especially analgesics, due to their expression in sensory
neurons and their critical role in nociception, particularly
in chronic pain states [37, 38].
The effective use of menthol depends on the understanding
that at higher doses of menthol, there may be off-target effects
as it is known to interact with other potentially nociceptive
TRP channels and voltage-sensitive channels [39, 40]. Very
high concentrations of topically applied menthol (40 %) are
overtly noxious and have been used to produce clinical pain
models [41], but there are likely to be numerous nonspecific
actions at this level.
In this study of topical menthol as an anti-neuropathic
agent, the effect was rapid with no dose titration re-
quired, which, combined with no apparent side effects,
is a clear potential advantage over other neuropathic
agents [19].
This work adds significantly to the increasing body of ev-
idence for the efficacy and safety of menthol and peppermint
oil as an analgesic in diverse pain states such as muscle strain,
migraine, irritable bowel syndrome, post-herpetic neuralgia
and CIPN [23, 24, 41–44] and true responders. Despite this,
not only did patient show a significant improvement in
pain relief, but this was supported by objective clinical
biomarker methodology and adherence to the IMMPACT
recommendations [25].
baseline 6 weeks
72%
(50/88) 
** 
24% 
(8/79) 
89% 
(78/93) 56% 
(20/77) 
Fig. 1 Outline of how abnormal
sensation in response to warm
stimulus (40 °C) decreased and
moved distally after 4–6 weeks of
menthol in patients with
chemotherapy-induced
neuropathy. **P<0.01 by
Wilcoxon-matched pairs test
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1. Patients were recruited from one specialist cancer centre
and findings may not apply to similar patients treated
elsewhere
2. It is possible that some patients may have had a sponta-
neous improvement in pain and function. However, this is
unlikely to have happened in the 6-week study timescale
in this patient group, who all had stable, established
chronic pain of at least 6 months duration.
The underlying neuropathic pain aetiology varied, however
there is accumulating evidence that aetiology is not the driving
factor in a treatment response, rather it is the neurobiological
changes in any individual, as characterised by QST, which
will determine response [45]. These characteristics were ex-
amined in detail in this study, using QST. The resolving numb-
ness along with normalisation of response to brush, cold and
warm, all moving in synchrony with resolving pain compared
with baseline, were important neurosensory biomarkers of
response. In this patient sample, it was not possible to identify
neurosensory predictors of response: this should be explored
in future studies.
It is important when investigating new treatments to exam-
ine in detail the characteristics of those who respond versus
those who do not respond. Analgesic studies are often
dismissed as negative, when in fact there is an important group
of responders hidden in the final result. It is accepted that not
all patients will respond to a treatment, no matter how prom-
ising that treatment. It is crucial however that relevant bio-
marker data are used to further identify and understand the
characteristics of a response. This approach makes identifica-
tion of responders more scientifically robust and acceptable.
In a randomised controlled trial of menthol, both study assess-
ments and a responder analysis will be facilitated by continu-
ing the biomarker work established in this proof of concept
study.
Implications for practice
Chronic established neuropathic pain is particularly difficult
to treat and represents a largely unmet therapeutic need. Al-
though progress has been made in curing and prolonging life
in patients with cancer, there are a number of long-term
Table 4 Comparison of the mean difference (change) between baseline and 6 weeks for responders and nonresponders (statistically significant P
values are set in bold)
4–6 weeks measure Nonresponder (n=19) Responder (n=19) P valuea
Mean difference (SD) or median (IQ range) Mean difference (SD) or median (IQ range)
n n
Clinical assessments
HADS
Total 18 −2.1 (4.1) 19 −3.0 (5.7) 0.589
Depression 18 −0.4 (2.2) 19 −1.1 (3.1) 0.459
Anxiety 18 −1.6 (2.4) 19 −1.8 (3.2) 0.807
PCS 17 −1.2 (7.5) 19 −8.1 (5.8) 0.004
LANSS (total) 19 −0.2 (4.3) 19 −2.4 (4.5) 0.129
Peg board (s)
Dominant hand 5 19 (41) 10 −25.7 (35.4) 0.048
Nondominant hand 5 6.8 (39.5) 10 −23.6 (35.2) 0.153
GAITRite
Velocity (m/s) 8 8.3 (22.9) 12 13.8 (16.8) 0.536
Cadence (steps/min) 8 2.3 (11.9) 12 7.8 (11.4) 0.310
QST
Mechanical detection threshold (g) 19 −0.24 (−3.4 to 0.26) 19 −0.26 (−0.78 to 0) 0.563a
Mechanical detection threshold NRS 19 0.0 (0.0 to 0.0) 19 0.0 (0.0 to 0.0) 0.418a
Mechanical pain threshold (g) 19 0.0 (−5 to 17) 19 0.0 (−16 to 86) 0.863a
Mechanical pain threshold NRS 19 −0.2 (3.5) 18 0.5 (2.0) 0.742
Windup ratio 19 0.0 (−2.0 to 0.63) 19 0.0 (−2.0 to 0.5) 0.729a
HADS Hospital Anxiety and Depression scale, LANSS Leeds Assessment of Neuropathic Symptoms and Signs, PCS Pain Catastrophising Scale, NRS
Numerial Rating Scale, 95 % CI 95 % confidence interval, IQ range interquartile range
a Exception—all compared using two-sample t test where Mann–Whitney U test used
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treatment-related problems (such as CIPN and PMPS) which
can limit further palliative chemotherapeutic options or impact
significantly on the patient's quality of life despite being cured
of cancer.
The discovery of the TRP channels has provided an oppor-
tunity for the development of analgesics, which are potentially
more specific for certain pain syndromes and have a better
side-effect profile than other interventions. TRP channels are
being investigated as novel targets for drug discovery; they
have a major advantage over more widely distributed voltage-
sensitive ion channels, in their potential for achieving analge-
sia without overwhelming side effects in neuropathic pain
[38]. This translational work with topical menthol, a TRPM8
agonist, shows significant promise, and points to the need for
further validation through a phase 2 double-blind efficacy
study.
If this preliminary work translates into positive further
phase 2/3 studies, then it could have a significant impact on
quality of life of both many patients being treated for cancer
and survivors of cancer.
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